Tips en el manejo de la hipertensión portal : experiencia de 11 años en un hospital de alta complejidad colombiano

Autor: Trujillo Calderón, Nasly Stephanie, Cárdenas Agudelo, Vanessa Carolina, Pierotty Carvajal, Mathieu, Caviedes González, José Gabriel, Roa Benavides, José Luis, Forero Melo, Julian Francisco, Pérez Hidalgo, Juan Manuel

Publikováno v: Boyer TD, Haskal ZJ. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology (Baltimore, Md). 2010;51(1):306.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

Propósito: Establecer las características clínicas de los pacientes llevados a Derivación Portosistémica Transyugular (TIPS), características del procedimiento y desenlace en un hospital colombiano de alta complejidad. Materiales y méto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bec7fbf87fc9c4f509a97ef490521958

Síndrome de pinzamiento femoroacetabular: manifestaciones clínicas y hallazgos por artroresonancia

Autor: Hortúa, Isaias, Nossa, Juan Manuel, Forero Melo, Julian Francisco, Pérez Hidalgo, Juan Manuel

Publikováno v: Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

El síndrome de pinzamiento femoroacetabular es una entidad reciente secundaria al “desacoplamiento” de la articulación coxofemoral, por alteración en la morfología de la cabeza femoral o del acetábulo, lo cual puede ocasionar osteoartrosis a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7bf0298175d411653fd1d240fd32af0

Sobrevida de los pacientes con carcinoma hepatocelular tratados con quimioembolización con microesferas cargadas: experiencia en un hospital de alta complejidad

Autor: Lara Cárdenas, July Patricia

Publikováno v: Chun S, Yu H, Chan SL, Lee KF, Wai J, Hui Y, et al. Ablative Chemoembolization for Hepatocellular Carcinoma : A Prospective Phase I Case-Control Comparison with Conventional. Radiology. 2018;000(0):1–9
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1
Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, et al. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clin Res Hepatol Gastroenterol. 2018;03(014):10
Hussain SM, Reinhold C, Mitchell DG. Cirrhosis and lesion characterization at MR imaging. Radiographics. 2009;29:1637–52
Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 Version of LI-RADS for CT and MR Imaging: An Update. RadioGraphics. 2017;37(7):1994– 2017
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101(February 2017):72–81
Edison J, Ort P, Carlos J, Guti R. Epidemiología y factores de riesgo. Asoc Colomb Gastroenterol Endosc Dig Coloproctología y Hepatol. 2013;7–11
Cortes-mancera F, Loureiro CL, Hoyos S, Restrepo J, Correa G, Jaramillo S, et al. Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat. 2011;2011:10
Lu SN, Wang JH, Su CW, Wang TE, Dai CY, Chen CH, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117(5):381–403
Parente DB, Perez RM, Araujo AE, Oliveira Neto JA, Marchiori E, Constantino CP, et al. MRI in hypervascular noduls in cyrrotic liver: A Diag-nostic Dilemma. RadioGraphics. 2012;32:767–87.
LI RADS [Internet]. Disponible en: https://www.acr.org/ClinicalResources/Reporting-and-Data-Systems/LI-RADS
Purysko AS, Remer EM, Coppa CP, Leão Filho HM, Thupili CR, Veniero JC. LI-RADS: A Case-based Review of the New Categorization of Liver Findings in Patients with EndStage Liver Disease. RadioGraphics. 2012;32(7):1977–95
Topalian SL, Drake CG, Pardoll DM. Perspective Immune Checkpoint Blockade : A Common Denominator Approach to Cancer Therapy. Cancer Cell [Internet]. 2015;27(4):450–61. Disponible en: http://dx.doi.org/10.1016/j.ccell.2015.03.001
Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Sherman M, Gores G. Hepatocellular carcinoma. Primer. 2016;2
Perez Hidalgo JM, Beltran OA. Tratamiento intervencionista. Asoc Colomb Gastroenterol Endosc Dig Coloproctología y Hepatol. 2013;28(3):21–7
Ahsun R, Khairuddin M, Frank H M, Paul N, Laura M K, Robert J L, et al. Role of EASL, RECIST and WHO Response Guidelines Alone or in Combination for Hepatocellular Carcinoma: Radiologic-Pathologic Correlation. J Hepatol. 2011;54(4):695 – 704
Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of Hepatocellular Carcinoma with Extrahepatic Collateral Blood Supply: Anatomic and Technical Considerations. RadioGraphics. 2017;37(3):963–77
Peng Z, Mei J, Qian G. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. 2019;(4)
De D, Sastre J, Martí-bonmati L, Llovet JM, Bilbao JI, Sangro B, et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH. 2016;(xx):1–22. Disponible en: https://servei.org/wpcontent/uploads/GPC_550_Carcinoma_Hepatocelular_2016.pdf
Cruz M, Hernández Martínez E, Correa A, Huitzil Meléndez LM, Vázquez FD. Embolización blanda vs . quimioembolización para tratamiento de carcinoma hepatocelular. Gac Mex Oncol. 2013;12(5):312–6
National Cancer Institute, Bethesda EU. Common Terminology Criteria for Adverse Events V3.0 (CTCAE). Cancer Ther Eval Progr 1-1. 2006
National Cancer Institute, Bethesda EU. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Cancer Institute. Cancer Ther Eval Progr. 2010
Yang H, Lee J, Lee DH, Kim H, Lee JM. Hepatocellular Carcinoma : Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology. 2014;271(3):909–18
Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, et al. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Cardiovasc Intervent Radiol. 2018;41(4):587–93
Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108(6):1252–9
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona2000 EASL conference. J Hepatol. 2001;35(3):421–30
Adulto DEL, Cantera CM, Familia M De, Passeig CAP, Joan DS, Català I, et al. Butlletí d ’ informació terapèutica. Butlletì d´informaciò Ter. 2017;28(9):67–74.
McEvoy SH, McCarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, et al. Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. RadioGraphics. 2013;33(6):1653–68
Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol. 2014;20(12):3069–77
Lencioni R, Llovet JM. Modified RECIST ( mRECIST ) Assessment for Hepatocellular Carcinoma. 2010;1(212):52–60
Dufour JF, Greten TF, Raymond E, Roskams T, De T, Ducreux M, et al. Clinical Practice Guidelines EASL – EORTC Clinical Practice Guidelines : Management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol [Internet]. 2012;56(4):908–43. Disponible en: http://dx.doi.org/10.1016/j.jhep.2011.12.001
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;Dec;5((6)):649–55
Sarasin F, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–34
Alejandro F, María E R, Carlos R, Jordi B. Current Strategy for Staging and Treatment-The BCLC Update and Future Prospects.pdf. Semin Liver Dis. 2010;30(1):61–74
Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2017;34(17):2046–53
Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol. 2017;67(1):173–83.
Llovet JM, Real MI, Montana X, Planas R. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

El carcinoma hepatocelular (CHC) es la segunda causa de muerte relacionada con cáncer a nivel global, en Colombia se estima una incidencia de 2 casos por cada 100.000 habitantes; a nivel mundial los virus de la hepatitis B y C conforman los factores

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a7fd8fd99b60ebbf9a40e475efd200
https://repository.urosario.edu.co/handle/10336/32176

Ablación percutánea por radiofrecuencia y microondas de lesiones focales hepáticas, experiencia en un hospital de alta complejidad

Autor: Aldana Silva, Carolina, Piñeros Nieto, Diego Alejandro

Publikováno v: Organization WH. International Agency for Research on Cancer.
American Cancer Society.
Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 Version of LI-RADS for CT and MR Imaging: An Update. RadioGraphics [Internet]. 2017 Nov 13 [cited 2020 Jun 1];37(7):1994–2017. Available from: http://pubs.rsna.org/doi/10.1148/rg.2017170098
MC N, I S, A C, D U, WA R, F C-M, et al. Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas From Colombia. Hepat Res Treat [Internet]. 2011 [cited 2020 Jun 11];2011. Available from: https://pubmed.ncbi.nlm.nih.gov/22114738/
El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–76.
Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol [Internet]. 2012;57(4):794–802. Available from: http://dx.doi.org/10.1016/j.jhep.2012.05.007
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology [Internet]. 2008 Jan [cited 2020 May 30];47(1):82–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18008357
McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Intervent Radiol. 2013;30(1):49–55.
Ziemlewicz TJ, Wells SA, Lubner MG, Brace CL, Lee FT, Hinshaw JL. Hepatic Tumor Ablation. Surg Clin North Am. 2016;96(2):315–39.
Lau WY, Lai ECH. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg [Internet]. 2009;249(1):20–5. Available from: papers3://publication/doi/10.1097/SLA.0b013e31818eec29
Luming Chen JS, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016;33(4):78–84.
HALSTED WS. The Results of Operations for the Cure of Cancer of the Breast Performed At the Johns Hopkins Hospital From June, 1889, To January, 1894. Ann Surg. 1894;20:497–555.
Rossi S, Fornari F, Buscarini L. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Interv Radiol. 1993;8(3):97–103.
Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16346 treated nodules in 13283 patients. Hepatol Res. 2012;42(11):1058–64.
A F, R V, C A, L B, M S, JR A, et al. Diagnosis of Hepatic Nodules 20 Mm or Smaller in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma. Hepatology [Internet]. 2008 [cited 2020 Jun 12];47(1). Available from: https://pubmed.ncbi.nlm.nih.gov/18069697/
K K, TK K, HJ J, MA H, L K, M G, et al. Optimization of Imaging Diagnosis of 1-2 Cm Hepatocellular Carcinoma: An Analysis of Diagnostic Performance and Resource Utilization. J Hepatol [Internet]. 2011 [cited 2020 Jun 12];54(4). Available from: https://pubmed.ncbi.nlm.nih.gov/21156219/
Bashir MR, Do Memorial RK, Kettering S, Center C, Fowler KJ, San UC, et al. LI-RADS ® v2018 CT/MRI Manual The LI-RADS ® v2018 Manual Writing Group Members Writing Group Members-in-Training [Internet]. [cited 2020 Jun 12]. Available from: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/LI-RADS-2018-Manual-5Dec18.pdf?la=en
Ronot M, Vilgrain V. Hepatocellular carcinoma: Diagnostic criteria by imaging techniques. Vol. 28, Best Practice and Research: Clinical Gastroenterology. 2014. p. 795–812.
R L, JM L. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis [Internet]. 2010 [cited 2020 Jun 12];30(1). Available from: https://pubmed.ncbi.nlm.nih.gov/20175033/
Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, et al. Locoregional Therapies for Hepatocellular Carcinoma and the New LI-RADS Treatment Response Algorithm. Abdom Radiol (New York) [Internet]. 2018 [cited 2020 Jun 12];43(1):218. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771991/
Zheng S-G, Xu H-X, Liu L-N. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol. 2014;6(1):7–14.
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–77; quiz 578.
Bouda D, Lagadec M, Alba CG, Barrau V, Burgio MD, Moussa N, et al. Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly. J Magn Reson Imaging. 2016;44(5):1070–90.
Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol. 2012;81(10):2730–6.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet [Internet]. 2018 Mar 31 [cited 2020 Jun 11];391(10127):1301–14. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30010-2/fulltext
Ruzzenente A, De Angelis M, Conci S, Campagnaro T, Isa G, Bagante F, et al. The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma. Transl Cancer Res [Internet]. 2018 [cited 2020 Jun 12];8(3):S233–44. Available from: http://tcr.amegroups.com/article/view/26077
IS O, DH S, TW K, MW L, W K, GY G, et al. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients With Very Early-Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation. Dig Dis Sci [Internet]. 2017 [cited 2020 Jun 12];62(11). Available from: https://pubmed.ncbi.nlm.nih.gov/28983724/
Chen P-C, Chiu N-C, Su C-W, Huang Y-H, Hou M-C, Lin H-C, et al. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. www.ejcma.org J Chin Med Assoc [Internet]. 2019 [cited 2020 Jun 12]; Available from: www.ejcma.org
Ni J-Y, An C, Zhang T-Q, Huang Z-M, Jiang X-Y, Huang J-H. Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma. Int J Hyperth [Internet]. 2019 Jan 1 [cited 2020 Jun 12];36(1):327–35. Available from: https://www.tandfonline.com/doi/full/10.1080/02656736.2019.1567834
Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–12.
Qi X, Tang Y, An D, Bai M, Shi X, Wang J, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2014;48(5):450–7.
Chok KS, Ng KK, Poon RTP, Lam CM, Yuen J, Tso WK, et al. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg. 2006;141(12):1231–6.
Nouso K, Kariyama K, Nakamura S, Oonishi A, Wakuta A, Oyama A, et al. Application of Radiofrequency Ablation for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. J Gastroenterol Hepatol [Internet]. 2016;(January 2001):695–700. Available from: http://doi.wiley.com/10.1111/jgh.13586
Murakami T, Ishimaru H, Sakamoto I, Uetani M, Matsuoka Y, Daikoku M, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: Rate and risk factors for local recurrence. Cardiovasc Intervent Radiol. 2007;30(4):696–704.
V M, E R, R D, S A, A P, F B, et al. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients With Cirrhosis. N Engl J Med [Internet]. 1996 [cited 2020 Jun 11];334(11). Available from: https://pubmed.ncbi.nlm.nih.gov/8594428/
Kim JH, Won HJ, Shin YM, Kim K-A, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 2011;196(2):W205–9.
Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003;90(10):1240–3.
Nieto IS de, Santaolaya M. Ablación por radiofrecuencia de los tumores hepáticos primarios y secundarios. An médicos. 2013;58(3):163–8.
Pugh RNH, Murray???Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.
JM L, R L. mRECIST for HCC: Performance and Novel Refinements. J Hepatol [Internet]. 2020 [cited 2020 Jun 12];72(2). Available from: https://pubmed.ncbi.nlm.nih.gov/31954493/
IBM. IBM SPSS Statistics for Macintosh. Armonk, NY: IBM Corp: IBM Corp; 2013.
Ding J, Jing X, Wang Y, Wang F, Wang Y, Du Z. Thermal ablation for hepatocellular carcinoma: a large-scale analysis of long-term outcome and prognostic factors. Clin Radiol. 2016;71(12):1270–6.
Zheng RN, You ZJ, Lin SH, Jia J, Cai YM, Liu C, et al. Efficacy of percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma. Genet Mol Res. 2015;14(4):17982–94.
DJ P, R S, E A, C Y, T A, K K, et al. The ALBI Grade Provides Objective Hepatic Reserve Estimation Across Each BCLC Stage of Hepatocellular Carcinoma. J Hepatol [Internet]. 2017 [cited 2020 Jun 13];66(2). Available from: https://pubmed.ncbi.nlm.nih.gov/27677714/?dopt=Abstract
Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer [Internet]. 2017 [cited 2020 Jun 13];6(3):204. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473065/
Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transplant [Internet]. 2005 Sep 1 [cited 2020 Jun 13];11(9):1117–26. Available from: http://doi.wiley.com/10.1002/lt.20469
Glassberg MB, Ghosh S, Clymer JW, Qadeer RA, Ferko NC, Sadeghirad B, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther [Internet]. 2019 [cited 2020 May 26];12:6407–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31496742
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

Introducción: El carcinoma hepatocelular (CHC) tiene alta prevalencia y tasa de mortalidad a nivel mundial. El manejo de CHC pequeños con técnicas locorregionales guiadas por imágenes en pacientes candidatos a trasplante hepático, funciona de ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f56963204afbe5267b1c8cbe930fef9
https://repository.urosario.edu.co/handle/10336/26518

Parámetros de la masa muscular medidos por tomografía computarizada en una población sana. Fundación Cardioinfantil – Instituto de Cardiología, Bogotá, 2014-2018

Autor: Villegas González, Valentina, Quintero Rodriguez, Katerine

Publikováno v: 1. Rosenberg I. Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. . Am J Clin Nutr; 1989 p. 1231–3
2. Murray TÉ, Williams D, Lee MJ. Osteoporosis, obesity, and sarcopenia on abdominal CT: a review of epidemiology, diagnostic criteria, and management strategies for the reporting radiologist. Abdominal Radiology. 2017:1-11.
3. Jentoft Ajc, Baeyens Jp, Bauer Jm, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: consenso europeo sobre su definición y diagnóstico. Informe del Grupo europeo de trabajo sobre la sarcopenia en personas de edad avanzada Oxfford University: Age and Ageing. 2010;39(4):412-23.
4. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014. Journal of cachexia, sarcopenia and muscle. 2014;5(4):253-9.
5. Von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. Journal of cachexia, sarcopenia and muscle. 2010;1(2):129-33.
6. Bischoff-Ferrari H, Orav J, Kanis J, Rizzoli R, Schlögl M, Staehelin H, et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporosis International. 2015;26(12):2793-802.
7. Liu P, Hao Q, Hai S, Wang H, Cao L, Dong B. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas. 2017.
8. Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transplantation. 2017;23(5):625-33.
9. Zuckerman J, Ades M, Mullie L, Trnkus A, Morin J-F, Langlois Y, et al. Psoas Muscle Area and Length of Stay in Older Adults Undergoing Cardiac Operations. The Annals of thoracic surgery. 2017;103(5):1498-504.
11. Zhou C-J, Zhang F-M, Zhang F-Y, Yu Z, Chen X-L, Shen X, et al. Sarcopenia: a new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy. Journal of Surgical Research. 2017;211:137-46.
12. Phillips A, Strobl R, Vogt S, Ladwig K-H, Thorand B, Grill E. Sarcopenia is associated with disability status—results from the KORA-Age study. Osteoporosis International. 2017:1-11.
13. Bucur P, Brustia R, Ciacio O, Bivol S, Soggiu F, Pittau G, et al. Definition of Sarcopenia in Cirrhotic Patients before Liver Transplantation. Liver Transplantation. 2013;19:S96-S7.
14. Cawthon PM, Fox KM, Gandra SR, Delmonico MJ, Chiou CF, Anthony MS, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? Journal of the American Geriatrics Society. 2009;57(8):1411-9.
15. Lang T, Cauley JA, Tylavsky F, Bauer D, Cummings S, Harris TB. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: The health, aging, and body composition study. Journal of Bone and Mineral Research. 2010;25(3):513-9.
16. Morosano M, Menoyo I, Tomat M, Masoni A, Pezzotto S. A simple anthropometric tool for the assessment of pre-sarcopenia in postmenopausal women. Climacteric. 2017:1-6.
17. Fukushima H, Yokoyama M, Nakanishi Y, Tobisu K-i, Koga F. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PloS one. 2015;10(1):e0115895.
18. Schweitzer L, Geisler C, Pourhassan M, Braun W, Glüer C-C, Bosy-Westphal A, et al. Estimation of Skeletal Muscle Mass and Visceral Adipose Tissue Volume by a Single Magnetic Resonance Imaging Slice in Healthy Elderly Adults. The Journal of nutrition. 2016;146(10):2143-8.
19. Kim H, Hirano H, Edahiro A, Ohara Y, Watanabe Y, Kojima N, et al. Sarcopenia: Prevalence and associated factors based on different suggested definitions in community-dwelling older adults. Geriatrics & gerontology international. 2016;16(S1):110-22.
20. Sinelnikov A, Qu C, Fetzer DT, Pelletier J-S, Dunn MA, Tsung A, et al. Measurement of skeletal muscle area: Comparison of CT and MR imaging. European journal of radiology. 2016;85(10):1716-21.
21. Abate N, Garg A, Coleman R, Grundy SM, Peshock RM. Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. The American journal of clinical nutrition. 1997;65(2):403-8.
22. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and ageing. 2018;48(1):16-31.
23. Byun S-E, Kim S, Kim K-H, Ha Y-C. Psoas cross-sectional area as a predictor of mortality and a diagnostic tool for sarcopenia in hip fracture patients. Journal of bone and mineral metabolism. 2019:1-9.
24. Shoreibah MG, Mahmoud K, Aboueldahab NA, Lune PV, Massoud M, Bae S, et al. Psoas Muscle Density in Combination with Model for End-Stage Liver Disease Score Can Improve Survival Predictability in Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology. 2019;30(2):154-61.
25. Huguet A, Latournerie M, Debry PH, Jezequel C, Legros L, Rayar M, et al. The psoas muscle transversal diameter predicts mortality in patients with cirrhosis on a waiting list for liver transplantation: a retrospective cohort study. Nutrition. 2018;51:73-9.
26. Rossi F, Valdora F, Barabino E, Calabrese M, Tagliafico AS. Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRI. European radiology. 2019;29(2):494-500.
27. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. Journal of applied physiology. 2000;89(1):104-10.
28. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism. 2008;33(5):997-1006.
29. Werf A, Langius J, Schueren M, Nurmohamed S, Pant K, Blauwhoff-Buskermolen S, et al. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. European journal of clinical nutrition. 2018;72(2):288.
30. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Scientific reports. 2018;8(1):11369.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

Objetivo: determinar la masa muscular por tomografía computarizada en una población sana, en la Fundación Cardioinfantil, Bogotá, 2014-2018. Materiales y métodos: estudio observacional descriptivo de una cohorte. Resultados: La mediana para la d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebe050c4e8a80f496128be5552367164
http://repository.urosario.edu.co/handle/10336/20019